The study focuses on adults with multiple myeloma that has returned after treatment or no longer responds to therapy (relapsed or refractory). These patients have previously received a medicine that targets CD38 (anti‑CD38 antibody) and the drug lenalidomide.
Two treatments are being compared. The experimental drug, identified by the code name JNJ-79635322, is a laboratory‑created protein that can bind to three different targets on cancer cells, helping the immune system recognize and attack them. The standard comparator is teclistamab, another laboratory‑created protein that works in a similar way. Both medicines are given as a subcutaneous injection (placed under the skin). The experimental agent is a type of monoclonal antibody, a class of drugs that act like a guided missile for the immune system.
The purpose of the trial is to compare how well the two drugs work in controlling the disease. Participants are randomly assigned to receive either the experimental drug or the comparator, with regular treatment sessions over several months and periodic clinic visits for safety checks and blood testing. The study continues until a predefined period has passed or the disease progresses.
Czechia 
France 
Germany 
Greece 
Italy 
Poland 
Spain 
